vs
阿斯利康（AZN）与GENMAB A/S（GMAB）财务数据对比。点击上方公司名可切换其他公司
阿斯利康的季度营收约是GENMAB A/S的15.6倍（$14.5B vs $925.0M）。GENMAB A/S净利率更高（36.3% vs 16.9%，领先19.4%）。GENMAB A/S同比增速更快（18.7% vs 11.7%）
阿斯利康是一家瑞典与英国合资的跨国制药及生物技术企业，总部位于英国剑桥的剑桥生物医学园区。公司产品管线覆盖肿瘤、心血管、消化、感染、神经科学、呼吸、炎症等重大疾病领域。
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
AZN vs GMAB — 直观对比
营收规模更大
AZN
是对方的15.6倍
$925.0M
营收增速更快
GMAB
高出7.0%
11.7%
净利率更高
GMAB
高出19.4%
16.9%
损益表 — Q2 2025 vs Q2 2025
| 指标 | | |
|---|---|---|
| 营收 | $14.5B | $925.0M |
| 净利润 | $2.4B | $336.0M |
| 毛利率 | 82.9% | 93.8% |
| 营业利润率 | 24.3% | 38.9% |
| 净利率 | 16.9% | 36.3% |
| 营收同比 | 11.7% | 18.7% |
| 净利润同比 | 27.0% | 65.5% |
| 每股收益（稀释后） | $1.57 | $5.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AZNGMAB
| Q2 25 | $14.5B | $925.0M | ||
| Q2 24 | $12.9B | $779.0M | ||
| Q2 23 | $11.4B | $604.5M | ||
| Q2 22 | $10.8B | $458.5M |
净利润AZNGMAB
| Q2 25 | $2.4B | $336.0M | ||
| Q2 24 | $1.9B | $203.0M | ||
| Q2 23 | $1.8B | $193.6M | ||
| Q2 22 | $360.0M | $274.2M |
毛利率AZNGMAB
| Q2 25 | 82.9% | 93.8% | ||
| Q2 24 | 83.1% | 96.4% | ||
| Q2 23 | 82.8% | 99.5% | ||
| Q2 22 | 72.2% | — |
营业利润率AZNGMAB
| Q2 25 | 24.3% | 38.9% | ||
| Q2 24 | 21.2% | 30.3% | ||
| Q2 23 | 21.5% | 35.2% | ||
| Q2 22 | 5.0% | 39.4% |
净利率AZNGMAB
| Q2 25 | 16.9% | 36.3% | ||
| Q2 24 | 14.9% | 26.1% | ||
| Q2 23 | 15.9% | 32.0% | ||
| Q2 22 | 3.3% | 59.8% |
每股收益（稀释后）AZNGMAB
| Q2 25 | $1.57 | $5.42 | ||
| Q2 24 | $1.24 | $3.13 | ||
| Q2 23 | $1.17 | — | ||
| Q2 22 | $0.23 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.1B | $1.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $44.8B | $5.3B |
| 总资产 | $112.4B | $6.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AZNGMAB
| Q2 25 | $7.1B | $1.3B | ||
| Q2 24 | $6.9B | $622.0M | ||
| Q2 23 | $5.7B | $1.6B | ||
| Q2 22 | $4.8B | $1.4B |
股东权益AZNGMAB
| Q2 25 | $44.8B | $5.3B | ||
| Q2 24 | $39.6B | $4.4B | ||
| Q2 23 | $37.4B | $4.1B | ||
| Q2 22 | $36.0B | $3.5B |
总资产AZNGMAB
| Q2 25 | $112.4B | $6.5B | ||
| Q2 24 | $104.3B | $5.6B | ||
| Q2 23 | $96.5B | $4.6B | ||
| Q2 22 | $96.6B | $4.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $349.0M |
| 自由现金流经营现金流 - 资本支出 | — | $327.0M |
| 自由现金流率自由现金流/营收 | — | 35.4% |
| 资本支出强度资本支出/营收 | — | 2.4% |
| 现金转化率经营现金流/净利润 | — | 1.04× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AZNGMAB
| Q2 25 | — | $349.0M | ||
| Q2 24 | — | $438.0M | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
自由现金流AZNGMAB
| Q2 25 | — | $327.0M | ||
| Q2 24 | — | $430.0M | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
自由现金流率AZNGMAB
| Q2 25 | — | 35.4% | ||
| Q2 24 | — | 55.2% | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
资本支出强度AZNGMAB
| Q2 25 | — | 2.4% | ||
| Q2 24 | — | 1.0% | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
现金转化率AZNGMAB
| Q2 25 | — | 1.04× | ||
| Q2 24 | — | 2.16× | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AZN
暂无分部数据
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
